Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate

Author: Benzinga Newsdesk | November 14, 2025 04:07pm
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.59) by 3.77 percent. This is a 91.92 percent increase over losses of $(20.41) per share from the same period last year.

Posted In: DRMA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist